RUNX1 and acute myeloid leukemia: Indeed, RUNX1-RUNX1T1–driven leukemic cell lines were among the most sensitive to several LSD1 inhibitors or LSD1 knockdown in a panel of AML, chronic myelogenous leukemia, and T-ALL cell lines (55).